These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19007431)

  • 1. Targeting the UPS as therapy in multiple myeloma.
    Chauhan D; Bianchi G; Anderson KC
    BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S1. PubMed ID: 19007431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patented small molecule inhibitors in the ubiquitin proteasome system.
    Guédat P; Colland F
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S14. PubMed ID: 18047738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition in multiple myeloma: therapeutic implication.
    Chauhan D; Hideshima T; Anderson KC
    Annu Rev Pharmacol Toxicol; 2005; 45():465-76. PubMed ID: 15822185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The UPS: a promising target for breast cancer treatment.
    Sato K; Rajendra E; Ohta T
    BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S2. PubMed ID: 19007432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ubiquitin system, disease, and drug discovery.
    Petroski MD
    BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S7. PubMed ID: 19007437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib as an antitumor agent.
    Roccaro AM; Hideshima T; Richardson PG; Russo D; Ribatti D; Vacca A; Dammacco F; Anderson KC
    Curr Pharm Biotechnol; 2006 Dec; 7(6):441-8. PubMed ID: 17168660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
    Driscoll JJ; Dechowdhury R
    Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
    Hideshima T; Anderson KC
    Semin Hematol; 2012 Jul; 49(3):223-7. PubMed ID: 22726545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the ubiquitin proteasome system in haematological malignancies.
    Crawford LJ; Irvine AE
    Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitor therapy in multiple myeloma.
    Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
    Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting.
    Nury D; Doucet C; Coux O
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S7. PubMed ID: 18047744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting proteasomes as therapy in multiple myeloma.
    Chauhan D; Hideshima T; Anderson KC
    Adv Exp Med Biol; 2008; 615():251-60. PubMed ID: 18437898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the ubiquitin proteasome system in Alzheimer's disease.
    Upadhya SC; Hegde AN
    BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S12. PubMed ID: 18047736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Classification and synthesis of ubiquitin-proteasome inhibitor].
    Li J; Zhang DY; Wu XM
    Yao Xue Xue Bao; 2009 Dec; 44(12):1313-9. PubMed ID: 21351462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
    Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
    Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V; Jacobs BS; Hussein MA
    Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
    Mittenberg AG; Kuzyk VO; Shabelnikov SV; Gorbach DP; Shatrova AN; Fedorova OA; Barlev NA
    Cell Cycle; 2018; 17(14):1745-1756. PubMed ID: 30009671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
    Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
    Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
    Johnson DE
    Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.